ORIC Pharmaceuticals, Inc. ORIC
9.59 USD +0.52 (+5.73%)
At closeNov 3, 2026, 4:01 PM EST
9.59 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
9.17 Day range 10.00
7.23 52-week range 14.68
- YTD
- +17.24%
- 1 year
- -24.43%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 21.64 +125.7% upside
Now 9.59
- Target (low)
- 14.00
- Target (mean)
- 21.64
- Target (high)
- 27.00
Ratings (0m) 16 15 buy · 1 hold · 0 sell
- Strong buy2
- Buy13
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 16
- 1 month ago 15
- 2 months ago 14
- 3 months ago 15
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.37887 | -0.45 – -0.32 | -0.33 | -14.8% | 0 | 0.0% | 13 |
| Next quarter | -0.39578 | -0.47 – -0.33713 | -0.30 | -31.9% | 0 | 0.0% | 13 |
| Current year | -1.49 | -1.64 – -1.25 | -1.47 | -1.3% | 0 | 0.0% | 13 |
| Next year | -1.67 | -1.91 – -1.37 | -1.49 | -12.4% | 0 | 0.0% | 13 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 5, 2026 | Leerink Partners | Initiated | — | Outperform |
| Sep 23, 2026 | BTIG | Initiated | — | Buy |
| Aug 10, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 8, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 15, 2026 | Goldman Sachs | Upgrade | — | Buy |
| May 5, 2026 | Citigroup | Maintained | Buy | Buy |
| Apr 2, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 1, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Mar 13, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 24, 2026 | Citigroup | Maintained | Buy | Buy |
| Feb 24, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 24, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Jan 13, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Jan 7, 2026 | Piper Sandler | Initiated | — | Overweight |
| Dec 8, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Dec 8, 2025 | Wedbush | Reiterated | Outperform | Outperform |
| Nov 20, 2025 | Evercore ISI Group | Initiated | — | Outperform |
| Nov 18, 2025 | Wolfe Research | Initiated | — | Peer Perform |
| Nov 18, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Nov 17, 2025 | Citigroup | Maintained | Buy | Buy |
| Nov 14, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 14, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Nov 14, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Aug 14, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 14, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 13, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Jul 8, 2025 | Ladenburg Thalmann | Initiated | — | Buy |
| May 19, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| May 9, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |